Sepsis - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 172 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Sepsis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Sepsis - Pipeline Review, H2 2014', provides an overview of the Sepsis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sepsis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Sepsis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Sepsis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Sepsis Overview 9
Therapeutics Development 10
Pipeline Products for Sepsis - Overview 10
Pipeline Products for Sepsis - Comparative Analysis 11
Sepsis - Therapeutics under Development by Companies 12
Sepsis - Therapeutics under Investigation by Universities/Institutes 15
Sepsis - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Sepsis - Products under Development by Companies 21
Sepsis - Products under Investigation by Universities/Institutes 25
Sepsis - Companies Involved in Therapeutics Development 26
Adrenomed AG 26
Advanced Cell Technology, Inc. 27
Altor BioScience Corporation 28
Aptose Biosciences Inc. 29
Asahi Kasei Pharma Corp. 30
Baxter International Inc. 31
Biomedica Management Corporation 32
Chiesi Farmaceutici SpA 33
Chiome Bioscience, Inc. 34
Cilian AG 35
Cognosci, Inc. 36
Diomune S.L 37
Endacea, Inc. 38
Evec, Inc. 39
Huons Co., Ltd. 40
Immune Response BioPharma, Inc. 41
ImmunNovative Developments SL 42
ISU ABXIS Co.,Ltd. 43
KAEL-GemVax Co., Ltd. 44
Lead Discovery Center GmbH 45
MSM Protein Technologies, Inc. 46
Navigen Pharmaceuticals, Inc. 47
Novadiscovery SAS 48
Noxxon Pharma AG 49
OncoImmune, Inc. 50
Opsona Therapeutics Ltd. 51
Serum Institute of India Limited 52
Silence Therapeutics plc 53
Syntiron LLC 54
Takeda Pharmaceutical Company Limited 55
TiGenix NV 56
VG Life Sciences, Inc. 57
XImmune AB 58
Sepsis - Therapeutics Assessment 59
Assessment by Monotherapy Products 59
Assessment by Target 60
Assessment by Mechanism of Action 62
Assessment by Route of Administration 64
Assessment by Molecule Type 66
Drug Profiles 68
3K3A-APC - Drug Profile 68
AB-022 - Drug Profile 70
AcPepA - Drug Profile 71
adrecizumab - Drug Profile 72
ALT-836 - Drug Profile 73
AM/AMBP-1 - Drug Profile 75
Anti-Semaphorin 3A Antibodies - Drug Profile 77
Atu-111 - Drug Profile 78
BaxB-01 - Drug Profile 79
BaxG-03 - Drug Profile 80
BaxM-159 - Drug Profile 81
BRL-44408 - Drug Profile 82
BTZO-2 - Drug Profile 83
COG-133 - Drug Profile 84
Cx-611 - Drug Profile 86
Drugs for Sepsis - Drug Profile 88
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 89
Drugs to Inhibit Sialidase for Sepsis - Drug Profile 90
EFP-306 - Drug Profile 91
Escherichia coli vaccine - Drug Profile 92
EV-007156 - Drug Profile 93
Glyco-23 - Drug Profile 94
HBN-1 - Drug Profile 95
HBN-3 - Drug Profile 96
HBN-4 - Drug Profile 97
HU-003 - Drug Profile 98
Human Ghrelin - Drug Profile 99
ImmStem - Drug Profile 100
ImmuneSafe - Drug Profile 101
ImmunNovative-02 - Drug Profile 102
IND-005 - Drug Profile 103
IR-999 - Drug Profile 104
ISU-201 - Drug Profile 105
klebsiella pneumoniae vaccine - Drug Profile 106
L-97-1 - Drug Profile 107
LB-1148 - Drug Profile 109
LOR-220 - Drug Profile 110
LR-17 - Drug Profile 111
M-33 - Drug Profile 112
meropenem - Drug Profile 113
Micselon - Drug Profile 114
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 115
Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 116
Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 117
Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 118
MSM-236 - Drug Profile 120
Nanotherapeutics - Drug Profile 121
NAV-838 - Drug Profile 122
NOXD-19 - Drug Profile 124
OPN-305 - Drug Profile 125
P-13 - Drug Profile 127
P-7 - Drug Profile 128
Proteins for Cardiovascular and Infectious Disease - Drug Profile 129
Recombinant Enzyme for Sepsis - Drug Profile 130
Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute radiation syndrome and Ischemic organ injury - Drug Profile 131
rhTFAM for Sepsis and Cognitive Disorders - Drug Profile 132
SIILPCV-10 - Drug Profile 134
Slit2N - Drug Profile 135
Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile 137
Small Molecule for Sepsis - Drug Profile 138
Small Molecule to Inhibit DDAH1 for Sepsis - Drug Profile 139
Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile 140
Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - Drug Profile 141
Synthetic Peptide to Inhibit TREM-1 for Cancer and Infectious Diseases - Drug Profile 142
Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile 143
Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile 144
Synthetic Peptides to Inhibit HSP90 for Oncology, Septic Shock, Inflammatory and Infectious Diseases - Drug Profile 145
Synthetic Peptides to Inhibit LPS for Bacterial and Viral Infections - Drug Profile 146
tertomotide - Drug Profile 147
thrombomodulin alfa - Drug Profile 149
VGV-S - Drug Profile 151
Yersinia pestis vaccine - Drug Profile 152
Sepsis - Recent Pipeline Updates 153
Sepsis - Dormant Projects 159
Sepsis - Discontinued Products 161
Sepsis - Product Development Milestones 162
Featured News & Press Releases 162
Appendix 166
Methodology 166
Coverage 166
Secondary Research 166
Primary Research 166
Expert Panel Validation 166
Contact Us 167
Disclaimer 167

List of Tables
Number of Products under Development for Sepsis, H2 2014 15
Number of Products under Development for Sepsis - Comparative Analysis, H2 2014 16
Number of Products under Development by Companies, H2 2014 18
Number of Products under Investigation by Universities/Institutes, H2 2014 21
Comparative Analysis by Late Stage Development, H2 2014 22
Comparative Analysis by Clinical Stage Development, H2 2014 23
Comparative Analysis by Early Stage Development, H2 2014 24
Comparative Analysis by Unknown Stage Development, H2 2014 25
Products under Development by Companies, H2 2014 26
Products under Development by Companies, H2 2014 (Contd..1) 27
Products under Development by Companies, H2 2014 (Contd..2) 28
Products under Development by Companies, H2 2014 (Contd..3) 29
Products under Investigation by Universities/Institutes, H2 2014 30
Sepsis - Pipeline by Adrenomed AG, H2 2014 31
Sepsis - Pipeline by Advanced Cell Technology, Inc., H2 2014 32
Sepsis - Pipeline by Altor BioScience Corporation, H2 2014 33
Sepsis - Pipeline by Aptose Biosciences Inc., H2 2014 34
Sepsis - Pipeline by Asahi Kasei Pharma Corp., H2 2014 35
Sepsis - Pipeline by Baxter International Inc., H2 2014 36
Sepsis - Pipeline by Biomedica Management Corporation, H2 2014 37
Sepsis - Pipeline by Chiesi Farmaceutici SpA, H2 2014 38
Sepsis - Pipeline by Chiome Bioscience, Inc., H2 2014 39
Sepsis - Pipeline by Cilian AG, H2 2014 40
Sepsis - Pipeline by Cognosci, Inc., H2 2014 41
Sepsis - Pipeline by Diomune S.L, H2 2014 42
Sepsis - Pipeline by Endacea, Inc., H2 2014 43
Sepsis - Pipeline by Evec, Inc., H2 2014 44
Sepsis - Pipeline by Huons Co., Ltd., H2 2014 45
Sepsis - Pipeline by Immune Response BioPharma, Inc., H2 2014 46
Sepsis - Pipeline by ImmunNovative Developments SL, H2 2014 47
Sepsis - Pipeline by ISU ABXIS Co.,Ltd., H2 2014 48
Sepsis - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 49
Sepsis - Pipeline by Lead Discovery Center GmbH, H2 2014 50
Sepsis - Pipeline by MSM Protein Technologies, Inc., H2 2014 51
Sepsis - Pipeline by Navigen Pharmaceuticals, Inc., H2 2014 52
Sepsis - Pipeline by Novadiscovery SAS, H2 2014 53
Sepsis - Pipeline by Noxxon Pharma AG, H2 2014 54
Sepsis - Pipeline by OncoImmune, Inc., H2 2014 55
Sepsis - Pipeline by Opsona Therapeutics Ltd., H2 2014 56
Sepsis - Pipeline by Serum Institute of India Limited, H2 2014 57
Sepsis - Pipeline by Silence Therapeutics plc, H2 2014 58
Sepsis - Pipeline by Syntiron LLC, H2 2014 59
Sepsis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 60
Sepsis - Pipeline by TiGenix NV, H2 2014 61
Sepsis - Pipeline by VG Life Sciences, Inc., H2 2014 62
Sepsis - Pipeline by XImmune AB, H2 2014 63
Assessment by Monotherapy Products, H2 2014 64
Number of Products by Stage and Target, H2 2014 66
Number of Products by Stage and Mechanism of Action, H2 2014 68
Number of Products by Stage and Route of Administration, H2 2014 70
Number of Products by Stage and Molecule Type, H2 2014 72
Sepsis Therapeutics - Recent Pipeline Updates, H2 2014 158
Sepsis - Dormant Projects, H2 2014 164
Sepsis - Discontinued Products, H2 2014 166